Effectiveness of Tocilizumab, Sarilumab, and Anakinra for critically ill patients with COVID-19 The REMAP-CAP COVID-19 Immune Modulation Therapy Domain Randomized Clinical Trial

The REMAP-CAP Investigators, Lennie P.G. Derde Writing committee on behalf of the investigators
doi: https://doi.org/10.1101/2021.06.18.21259133

Data Availability

Data will be available to researchers on request subject to sponsor restrictions, please contact cameron.green{at}monash.edu

http://www.remapcap.org

Back to top
Posted June 25, 2021.
Download PDF

Supplementary Material

Data/Code
Email
Effectiveness of Tocilizumab, Sarilumab, and Anakinra for critically ill patients with COVID-19 The REMAP-CAP COVID-19 Immune Modulation Therapy Domain Randomized Clinical Trial
The REMAP-CAP Investigators, Lennie P.G. Derde
medRxiv 2021.06.18.21259133; doi: https://doi.org/10.1101/2021.06.18.21259133
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area